Dublin-based Carrick Therapeutics Ltd. has licensed exclusive worldwide rights to develop and commercialize BTG945, now known as CT900, an investigational targeted ovarian cancer drug, from BTG PLC for an undisclosed sum.
CT900 combines targeting folate receptor α (FRα) and inhibiting thymidylate synthase
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?